ibidi
Solving Real-World Biomedical Problems with Cellular Microscopy

Live-cell microscopy has become an indispensable tool in cell biology laboratories, providing real-time insights into cellular dynamics. It enables the direct observation of cellular vitality, protein interactions, and drug target assessment. However, executing successful cell-based assays under the microscope can pose challenges for research teams. A key obstacle lies in maintaining cells in a healthy state on the microscope stage, demanding precise environmental control.

This is where ibidi excels. As a leading provider of cell-based assays and products for cellular microscopy, ibidi helps create an environment conducive to highly quantifiable and reproducible assays. This environment closely mimics natural cell conditions, offering evidence-based insights into cellular and tissue functions to drive successful research outcomes.

“ibidi was founded by young scientists, guided by enthusiasm for science and a mission to combat scourges of humanity, such as cancer and cardiovascular diseases,” says Dr. Roman Zantl, co-founder, and CEO of ibidi together with Dr. Valentin Kahl.

The company is powered by a tightly-knit team of industry-leading physicists, biologists, and engineers. They collaborate to pioneer innovative products and solutions for scientists worldwide. This dedicated team effectively transforms cutting-edge technologies into solutions that drive advances in cell-based research. Their work empowers the exploration of critical diseases such as cancer, cardiovascular conditions, and autoimmune disorders.

Undoubtedly, the team’s commitment to innovation, quality, and exceptional service has established the company as a trusted partner. They specialize in delivering functional cell-based assays and advanced products for cellular microscopy, primarily serving academia, as well as biotech and pharma enterprises.

ibidi’s products find widespread use in the field of oncology, given their excellence in generating improved scientific conclusions with minimal effort. A testament to this is the firm’s innovative assay designed to quantitatively measure the cell kill efficiency of cytotoxic immune cells against cancer cells. Research teams can use it to directly observe the cells at work while reducing the oxygen concentration to typical levels in tissues or even tumors.

This is ideal for making the results truly relevant, as maintaining optimal oxygen concentrations impacts cell metabolism and enhances the accuracy of research outcomes. Having this ability has enabled ibidi to address the challenges associated with cancer drug development and reshape the biomedical research landscape.

At the request of clients, ibidi has developed a video microscopy-based assay to support research on customized cancer therapeutics. This assay allows for the study of single-cell migration of tumor cells in chemical gradients, providing a deeper understanding of metastasis mechanisms.

“We have an unmatched range of technologies to create a cell environment for these living cell studies, including surface technologies, various sample chambers, and perfusion systems,” says Dr. Zantl. “Our products are designed with a mission to keep cells happy throughout the process.”

ibidi was founded by young scientists, guided by the enthusiasm for science and the mission to fight and defeat the scourges of humanity such as cancer and cardiovascular diseases

ibidi also plays a pivotal role in advancing the understanding of metastasis. Its perfusion system enables endothelial cells to be cultured under flow, efficiently simulating the structure of in vivo endothelium. Here, researchers can use its rolling and adhesion assays to study how tumor cells in the bloodstream adhere to endothelial cells and subsequently transmigrate through the layer of endothelial cells. Its solutions for cultivating tumor spheroids under flow conditions have witnessed a surge in demand recently. Under flow conditions, tumor spheroids develop into well-defined, compact microtumors, mirroring the nutrient supply observed in living organisms.

This dynamic growth environment, unlike static conditions, allows tumor spheroids to reach larger sizes, providing a more accurate simulation of real tumors, particularly during the stage at which modern diagnostic techniques detect them. ibidi’s contributions empower researchers to delve deeper into the complexities of cancer biology, driving progress in oncology research.

ibidi measures its success by the success of its clients. For this reason, the company has specifically built its portfolio of technologies around the topic of cell environments. Based on this, it develops solutions for performing assays that are easy to use while delivering quantitative, reproducible, and valid results. Its German roots and indisputable quality management systems with ISO certifications 9001 and 13485 underscore its unwavering commitment to deliver the best to clients.

ibidi’s innovative products and value proposition have resonated throughout the global scientific community, earning fervent acclaim among universities and pharmaceutical giants. Notably, its brilliance shone when DLR and Airbus Defence and Space embarked on a quest for life support systems on the ISS. In the face of unforgiving space constraints, ibidi’s ingenuity delivered an elegant solution, elevating cell viability and precision incubation beyond all bounds.

With numerous successes to its name, ibidi is poised for future growth and innovation, driven by the mission to equip scientists with standardized workflows that yield objective scientific data, shaping tomorrow’s life-changing therapies.